Search

Your search keyword '"Kouchoukos, Nicholas T."' showing total 899 results
Start Over Author "Kouchoukos, Nicholas T."
899 results on '"Kouchoukos, Nicholas T."'

21. Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial

Author

Koshizaka, Masaya, Lopes, Renato D., Reyes, Eric M., Gibson, Michael C., Schulte, Phillip J., Hafley, Gail E., Hernandez, Adrian F., Green, Jennifer B., Kouchoukos, Nicholas T., Califf, Robert M., Ferguson, Bruce T., Peterson, Eric D., and Alexander, John H.

Published
2015
Full Text
View/download PDF

28. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery

Author

Lopes, Renato D., Hafley, Gail E., Allen, keith B., Ferguseon, T. Bruce, Peterson, Eric D., Harrington, Robert A., Mehta, Rajendra H., Gibson, C. Michael, Mack, Michael J., Kouchoukos, Nicholas T., Califf, Robert M., and Alexander, John H.

Subjects
Coronary artery bypass -- Complications and side effects, Endoscopic surgery -- Evaluation, Endoscopy -- Evaluation, Surgery -- Complications, Surgery -- Control, Veins -- Transplantation, Veins -- Patient outcomes
Abstract

A study was conducted to evaluate the efficacy of endoscopy with open vein-graft harvesting in reducing post-operative wound complications after coronary-artery bypass surgery. Results indicated that this kind of vein grafting is independently associated with vein-graft failure and negative outcomes.

Published
2009

31. Surgical Ventricular Restoration: The RESTORE Group Experience

Author

Athanasuleas, Constantine L., Buckberg, Gerald D., Stanley, Alfred W. H., Siler, William, Dor, Vincent, Donato, Marisa Di, Menicanti, Lorenzo, de Oliveira, Sergio Almeida, Beyersdorf, Friedhelm, Kron, Irving L., Suma, Hisayoshi, Kouchoukos, Nicholas T., Moore, Wistar, McCarthy, Patrick M., Oz, Mehmet C., Fontan, Francis, Scott, Meredith L., Accola, Kevin A., and The RESTORE Group

Published
2005
Full Text
View/download PDF

32. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics

Author

Alexander, John H., Ferguson, T. Bruce, Jr., Joseph, Diane M., Mack, Michael J., Wolf, Randall K., Gibson, C. Michael, Gennevois, Daniel, Lorenz, Todd J., Harrington, Robert A., Peterson, Eric D., Lee, Kerry L., Califf, Robert M., and Kouchoukos, Nicholas T.

Subjects
Corgentech Inc. -- Product development, Gene therapy -- Research, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Coronary artery bypass -- Complications and side effects, Hyperplasia -- Prevention, Veins -- Transplantation, Veins -- Care and treatment, Health
Published
2005

36. Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.

Author

Kulik, Alexander, Abreu, Amy M., Boronat, Viviana, Kouchoukos, Nicholas T., and Ruel, Marc

Abstract

Background: Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal postoperative antiplatelet regimen remains unclear. The goal of the Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) trial was to assess whether early postoperative ticagrelor reduces SVG occlusion compared to conventional aspirin therapy. Methods: In this multi‐center double‐blind randomized trial, 250 patients who had CABG with SVG were randomized to receive either aspirin 81 mg twice daily or ticagrelor 90 mg twice daily. The primary outcome was SVG occlusion at 1 year. Results: Altogether, 123 patients were randomized to aspirin and 127 received ticagrelor. One‐year graft assessment was performed in 202 patients (80.8%), examining 588 grafts, yielding an overall graft occlusion rate of 10.9%. The primary outcome, SVG occlusion at 1 year, did not significantly differ between the two groups (17.4% vs. 13.2%, aspirin vs. ticagrelor, p =.30). The incidence of vein grafts with any disease (stenosis or occlusion) did not significantly differ between the groups (21.5% vs. 22.3%, aspirin vs. ticagrelor, p =.90), and the number of patients with vein graft disease did not significantly differ between the groups (29.4% vs. 28.0%, aspirin vs. ticagrelor, p =.88). Freedom from major adverse cardiovascular events at 1 year was similar between the groups (p =.60). Conclusions: Compared to conventional aspirin therapy, ticagrelor did not significantly reduce vein graft occlusion 1 year after CABG. Further study will assess the impact of ticagrelor on 2‐year graft patency for this cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results